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DEA Reschedules Hydrocodone 
Combination Products as Schedule II
Drug Enforcement Administration (DEA) has published its final 
rule rescheduling hydrocodone combination products (HCPs) from 
Schedule III to Schedule II in the Federal Register. The change 
imposes Schedule II regulatory controls and sanctions on anyone 
handling HCPs, effective October 6, 2014. DEA first published 
the proposed rules in March 2014 in response to a Food and Drug 
Administration (FDA) recommendation. DEA received almost 
600 public comments regarding the proposed rules after they were 
published, with a small majority of the commenters supporting the 
change, DEA notes in a press release, which is available at www 
.justice.gov/dea/divisions/hq/2014/hq082114.shtml.
The announcement is available on the Federal Register web-
site at https://federalregister.gov/articles/2014/08/22/2014-19922/
schedules-of-controlled-substances-rescheduling-of-hydrocodone-
combination-products-from-schedule.
DEA Classifies Tramadol a Controlled 
Substance
Under a final rule published in the Federal Register, the pain 
reliever tramadol is now classified as a Schedule IV controlled 
substance (CS). As of August 18, 2014, DEA requires manufacturers 
to print the “C-IV” designation on all labels that contain 
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol 
(tramadol), including its salts, isomers, and salts of isomers. The 
agency noted that every “DEA registrant who possesses any 
quantity of tramadol on the effective date of this final rule must 
take an inventory of all stocks of tramadol on hand as of August 18, 
2014, pursuant to 21 U.S.C. 827 and 958, and in accordance with 
21 CFR 1304.03, 1304.04, and 1304.11 (a) and (d).” In addition, all 
“prescriptions for tramadol or products containing tramadol must 
comply with 21 U.S.C. 829, and be issued in accordance with 21 
CFR part 1306 and subpart C of 21 CFR part 1311 as of August 
18, 2014.”
The announcement is available on the Federal Register web-
site at www.federalregister.gov/articles/2014/07/02/2014-15548/
schedules-of-controlled-substances-placement-of-tramadol-into-
schedule-iv.
Root Causes: A Roadmap to Action
The following two articles were prepared 
by the Institute for Safe Medication Practices 
(ISMP). ISMP is an independent nonprofit 
agency and federally certified patient safety organization that 
analyzes medication errors, near misses, and potentially hazard-
ous conditions as reported by pharmacists and other practitioners. 
ISMP then makes appropriate contacts with companies and regu-
lators, gathers expert opinion about prevention measures, and 
publishes its recommendations. To read about the risk reduction 
strategies that you can put into practice today, subscribe to ISMP 
Medication Safety Alert!® Community/Ambulatory Care Edition 
by visiting www.ismp.org. ISMP provides legal protection and 
confidentiality for submitted patient safety data and error reports. 
Help others by reporting actual and potential medication errors to 
the ISMP National Medication Errors Reporting Program Report 
online at www.ismp.org. E-mail: ismpinfo@ismp.org.
Errors are almost never caused by the failure of a single element 
in the system. More often, there are multiple underlying system 
failures that lead to an error, many of which can be identified when 
the involved health care providers take the time to uncover them.
Consider the following error: A doctor sent a handwritten order 
for carbamazepine 400 mg twice daily for an adult patient with a 
history of seizures.
The pharmacist entered the medication into the profile of a 
four-year-old child with the same last name as the adult patient for 
whom the medication had been prescribed. 
The pharmacist failed to notice that the patient was a child, as age 
was not in a prominent location on the order entry screen. The nurse 
failed to recognize that the dose was too high and administered 
400 mg of carbamazepine to the child. She also never thought to 
question why the pharmacy would send oral tablets for a four-year-
old child, considering that the drug is available in chewable tablets 
and as a liquid suspension.
The nurse assumed that the child was receiving the medication 
because he had a history of seizures. However, the nurse did not 
check the patient’s medical record. In fact, the child did not have 
a history of seizures.
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The parents had a very limited understanding of English, so they 
were unable to intervene to correct the erroneous seizure history.
The error was finally detected after the child became lethargic 
and developed nausea and vomiting. At the time of discovery, the 
child’s carbamazepine level was 18 mcg/mL; levels greater than 
12 in pediatric patients are supratherapeutic.i
It may be discouraging to see how many things go wrong when 
a medication error reaches a patient. However, a thorough root 
cause analysis (RCA) can uncover the latent failures and produce 
an action plan to avoid future errors.
ISMP, through a generous grant from the National Association 
of Boards of Pharmacy Foundation™, has developed the Root Cause 
Analysis Workbook for Community/Ambulatory Pharmacy. The 
workbook is designed to assist community pharmacy personnel 
in completing RCA for a sentinel event that may have occurred in 
their pharmacy. The RCA workbook uses a specific set of steps and 
associated tools to identify the primary causes of the sentinel event.
The goal of the RCA is to create an action plan framework, includ-
ing risk-reduction strategies, communication and implementation 
strategies, and measurement of effectiveness.
RCA for sentinel events is required in the Center for Pharmacy 
Practice Accreditation® standards developed by NABP, American 
Pharmacists Association, and American Society of Health-System 
Pharmacists Association, as well as by several boards of pharmacy 
in conjunction with their continuous quality improvement regula-
tions. 
This ISMP RCA workbook is suitable for use in community 
pharmacy, mail-order pharmacy, or other ambulatory pharmacy 
practice settings that need to investigate a sentinel event. For more 
information and to access the free workbook, visit www.ismp.org/
tools/rca.
ihttp://pediatrics.aappublications.org/content/113/2/406.abstract
The mL-Only Standard for Liquid Dosing 
Gathers Steam
ISMP first reported on the confusion of teaspoonfuls and mil-
liliters (mL) in its newsletter in 2000, and in 2009, issued a call for 
practitioners to move to sole use of the metric system for measuring 
over‐the-counter and prescription oral liquid doses, but mix‐ups 
have continued to result in the serious injury of children and adults. 
Use of the metric system alone when prescribing, dispensing, and 
administering medications would prevent mix‐ups because there 
would only be one method used to communicate and measure doses.
The health care industry is beginning to acknowledge the risk of 
confusion when using non‐metric measurements, especially with 
oral liquid medications. The National Council for Prescription 
Drug Programs (NCPDP) released a white paper entitled NCPDP 
Recommendations and Guidance for Standardizing the Dosing 
Designations on Prescription Container Labels of Oral Liquid 
Medications. More information about the white paper is summa-
rized in the next article.
The white paper comes as welcome news and is well-aligned 
with the ISMP 2014-15 Targeted Medication Safety Best Practices 
for Hospitals, Best Practice 5, which calls for organizations to use 
oral liquid dosing devices (oral syringes/cups/droppers) that only 
display the metric scale. The white paper also comes at a time when 
the Centers for Disease Control and Prevention, ISMP, the Consumer 
Healthcare Products Association, the United States FDA, the US 
Metric Association, and the American Academy of Pediatrics have 
initiatives in place that will help guide health care organizations to 
commit to metric measurements.
ISMP recommends the following actions to help prevent errors:
 ♦ Use only metric units, not teaspoon or other non‐metric 
measurements, for all patient instructions, including those 
listed in prescribing and pharmacy computer systems. This 
should cover directions incorporated into computer system 
mnemonics, speed codes, or any defaults used to generate 
prescriptions and prescription labels.
 ♦ Take steps to ensure patients have an appropriate device to 
measure oral liquid volumes in milliliters.
 ♦ Coach patients on how to use and clean measuring devices; 
use the “teach back” approach and ask patients or caregivers 
to demonstrate their understanding.
NCPDP Recommends Standardized Metric 
Measurements on Oral Liquid Medication 
Labels
NCPDP has issued new recommendations and guidance for 
standardizing the dosing designation used on prescription container 
labels of oral liquid medications dispensed by community pharma-
cies in order to reduce dosing errors. NCPDP notes that such errors 
have been “a source of concern for many years,” and that dosing 
errors involving young children are of particular concern because 
they may be more susceptible to harm from measurement errors and 
overdoses. The white paper outlines the following recommendations 
for the dosing designation on prescription container labels for oral 
liquid medications:
 ♦ The millimeter (mL) should be used as a standard unit of 
measurement.
 ♦ Dose amounts should always use leading zeros before 
decimal points for amounts less than one and should not use 
trailing zeros after a decimal point.
 ♦ Dosing devices with numeric graduations and units 
corresponding to the container label should be made easily 
and universally available. For example, a device should be 
included with each dispensed medication.
The white paper was developed following a meeting with stake-
holders representing 27 participants, including NABP. In addition 
to its general recommendations, the white paper also issued calls 
to action for relevant stakeholders, including government agencies, 
standards organizations, pharmacists and pharmacy technicians, 
pharmacy leadership, and health care associations.
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The white paper is available for download from the NCPDP 
website at http://ncpdp.org/Education/Whitepaper.
FDA Lowers Recommended Starting 
Dose for Lunesta Due to Risk of Morning 
Impairment
FDA has lowered the recommended starting dose of the sleep 
drug Lunesta® (eszopiclone) from 2 mg to 1 mg. Patients who are 
currently taking 2 mg and 3 mg doses of eszopiclone should contact 
their health care provider to ask for instructions on how to continue 
to take their medication safely at a dose that is best for them, FDA 
advises. The dose change came after findings from a study of 91 
healthy adults found that the medication was associated with impair-
ment to driving skills, memory, and coordination for as long as 11 
hours after the drug is taken, FDA notes. 
More information is available in an FDA news release at www.fda 
.gov/newsevents/newsroom/pressannouncements/ucm397453.htm.
Lidocaine Should Not Be Used to Treat 
Teething Pain in Children, FDA Warns
FDA is recommending that prescription oral viscous lidocaine 
2% solution should not be used to treat infants and children with 
teething pain, and is now requiring a new boxed warning to be 
added to the drug label to highlight this information. Oral viscous 
lidocaine solution is not approved to treat teething pain, and use in 
infants and young children can cause serious harm, including death, 
indicates FDA in a June 2014 safety announcement. FDA advises 
health care providers not to prescribe or recommend this product for 
teething pain. FDA is also requiring the “Warnings” and “Dosage 
and Administration” sections of the drug label to describe the risk 
of severe adverse events and to include additional instructions for 
dosing when the drug is prescribed for approved uses.
In 2014, FDA reviewed 22 case reports of serious adverse reac-
tions, including deaths, in infants and young children who were either 
given lidocaine for treatment of mouth pain, or who accidentally 
ingested the medication. 
More information is available in the safety announcement on 
FDA’s website at www.fda.gov/Drugs/DrugSafety/ucm402240.htm.
FDA Reiterates Warning Against Using 
NuVision Pharmacy Products
Health care providers should not use or distribute compounded 
drugs marketed as sterile produced by Downing Labs, LLC, of 
Dallas, TX, also known as NuVision Pharmacy, warns FDA. 
Inspection results issued on July 16, 2014, indicate that FDA observed 
unsanitary conditions resulting in a lack of sterility assurance of 
sterile drug products produced by the company, which may put 
patients at risk, FDA notes in the safety announcement. “The 
inspection revealed sterility failures in 19 lots of drug products 
intended to be sterile, endotoxin failures in three lots of drug 
products, and inadequate or no investigation of these failures,” states 
FDA in the announcement.
In 2013, the agency issued several similar warnings following 
NuVision’s refusal to recall all sterile products. In April 2013, NuVi-
sion recalled methylcobalamin injection and lyophilized injection 
products, citing concerns about sterility in the wake of adverse event 
reports. Health care providers and consumers may report adverse 
events or quality problems associated with NuVision products to 
FDA’s MedWatch Safety Information and Adverse Event Report-
ing Program.
Additional information is available in the safety announcement, 
available on FDA’s website at www.fda.gov/Drugs/DrugSafety/
ucm405940.htm.
JCPP Releases New Patient-Care 
Document to Promote Consistency
The Joint Commission of Pharmacy Practitioners (JCPP) has 
released a resource document aimed at promoting consistency in the 
pharmacists’ process of patient care service delivery. “Pharmacists’ 
Patient Care Process” was developed by examining key source docu-
ments on pharmaceutical care and medication therapy management. 
The document describes the process in five parts: collect, assess, 
plan, implement, and follow-up.
JCPP brings together the chief executive officers and elected of-
ficers of national pharmacy associations, including NABP, to create 
a forum for discussion and opportunity for collaborative work on 
issues and priorities of pharmacy practice.
The document can be downloaded online at www.pharmacist.com/
sites/default/files/JCPP_Pharmacists_Patient_Care_Process.pdf.
CPE Credit Offered for FDA Course on 
Misleading Prescription Drug Promotion
To raise awareness about the risks associated with false or 
misleading prescription medication marketing, FDA, in partner-
ship with Medscape, is offering an online, one-hour continuing 
education course through its Bad Ad Program. Pharmacists may 
receive continuing pharmacy education (CPE) credit by taking this 
course. Learning objectives, faculty information, and other infor-
mation is available on the course’s website at www.sigmatech.com/ 
BadAd. There is no registration fee for the course. Upon completion, 
pharmacists will receive one Accreditation Council for Pharmacy 
Education-accredited CPE hour (0.1 continuing education unit).
FDA Withdraws Approval of Some High 
Dose Acetaminophen Products
FDA is withdrawing approval of 108 abbreviated new drug ap-
plications (ANDAs) for prescription combination drug products 
containing more than 325 mg of acetaminophen per dosage unit. 
For the 108 ANDAs, the manufacturers asked to withdraw their 
applications, as announced in the March 27, 2014 Federal Register 
notice. A second Federal Register notice addresses the applica-
tions of six manufacturers who have discontinued marketing their 
products, but who have not withdrawn their applications. The notice 
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also announces FDA’s intention to begin the process of withdrawing 
approval of those applications.
In light of these announcements, and to protect patients from 
inadvertent acetaminophen overdose, NABP advises that pharma-
cies no longer dispense combination drugs containing more than 
325 mg of acetaminophen per dosage unit. NABP also advises that 
pharmacists consult with prescribers to discuss alternative products 
with lower acetaminophen doses.
FDA asked manufacturers to voluntarily withdraw these prod-
ucts from the market to reduce the risk of severe liver injury from 
inadvertent acetaminophen overdose. In January 2014, FDA recom-
mended that providers consider prescribing acetaminophen products 
containing 325 mg or less per dose.
The original announcement may be found in the Drug Safety 
and Availability section of FDA’s website at www.fda.gov/Drugs/
DrugSafety.
New Educational Video for Pharmacists 
Addresses Prescription Drug Abuse
NABP and the Anti-Diversion Industry Working Group, a con-
sortium of pharmaceutical manufacturers and distributors of CS, 
have released an educational video for pharmacists to help them 
identify the warning signs of prescription drug abuse and diversion 
when dispensing CS prescriptions. The video, entitled “Red Flags,” 
encourages pharmacists to help combat this national problem by 
exercising their professional judgment to ensure that the prescrip-
tions they dispense were written for a legitimate medical purpose, 
and to act upon any unusual behavior they observe.
DEA and various state pharmacy boards have described “red 
flags” as circumstances surrounding the presentation of a CS pre-
scription that should raise reasonable suspicion about the validity of 
that prescription. The video highlights a number of these potential 
warning signs, some of which are not easy to spot, by weaving 
personal narratives with interactions between pharmacists and 
customers.
The video is available in the Pharmacists section of the 
AWARXE® Prescription Drug Safety website at www.AWARErx.org/ 
pharmacists.
USP Proposes New General Chapter 
Addressing Compounding of Hazardous 
Drugs
In an effort to protect health care providers and personnel who 
handle hazardous drugs, United States Pharmacopeial Conven-
tion (USP) proposed new General Chapter <800> Hazardous 
Drugs—Handling in Healthcare Settings. The new proposed chapter 
addressed standards that apply to all personnel who compound 
hazardous drug preparations and all places where hazardous drugs 
are prepared, stored, transported, and administered. Comments on 
the proposed chapter were accepted until July 31, 2014, and have 
been reviewed by the Compounding Expert Committee. A revised 
version of the proposed chapter reflecting new guidance documents 
and stakeholder input will be available in spring 2015.
Additional details are included in a USP announcment at www 
.usp.org/usp-nf/notices/general-chapter-hazardous-drugs- 
handling-healthcare-settings.
Board Website
Please visit the Iowa Board of Pharmacy’s website at www 
.state.ia.us/ibpe. 
Follow the Board on Facebook and Twitter
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and protects 
the public health, safety, and welfare through the effective regula-
tion of the practice of pharmacy and the licensing of pharmacies, 
pharmacists, and others engaged in the sale, delivery, or distribu-
tion of prescription drugs and devices. Iowa Code §155A.2(1).
